Hetero’s generic 0.89- and 1.34-milligram tablets of tivozanib hydrochloride—Fotivda’s active ingredient—infringe Aveo’s US Patent No. 11,504,365, according to a complaint filed Friday in the US District Court for the District of Delaware.
- The patent expires in November 2039—the latest of the three patents listed for Fotivda in the US Food and Drug Administration’s registry of approved drugs, the Orange Book. It covers a way to treat ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.